A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
Related Experiment Video
Updated: Oct 26, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Cheong E Von1, Ho Gwo Fuang1,2
1Department of Clinical Oncology, First Floor Menara Timur, University of Malaya Medical Centre, Lembah Pantai, 59100, Kuala Lumpur, Malaysia.
Abstract:
The development of resistance to tyrosine kinase inhibitors (TKIs) in metastatic non-small cell lung cancer (NSCLC) with oncogenic driver mutations highlights the challenge in improving the survival of these patients. The standard of care for ALK-rearranged advanced NSCLC refractory to various generations of ALK TKIs falls back to the use of chemotherapy and the prognosis remains poor. We report the case of a 41-year-old lady with an ALK-translocated metastatic lung adenocarcinoma, who demonstrated good response to an immune checkpoint inhibitor, atezolizumab in combination with bevacizumab and chemotherapy (pemetrexed and carboplatin), following disease progression on three generations of ALK TKIs. Six months into treatment, she continues to show improvement in her health-related quality of life and is tolerating treatment well. Our case suggests that this treatment regimen is a potential treatment option for TKI-refractory driver-mutated NSCLC.
Insights
For advanced non-small cell lung cancer (NSCLC) resistant to tyrosine kinase inhibitors (TKIs), a combination of atezolizumab, bevacizumab, and chemotherapy shows promise. This regimen improved a patient's quality of life, offering a potential new option.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- Resistance to tyrosine kinase inhibitors (TKIs) is a significant challenge in treating metastatic non-small cell lung cancer (NSCLC) with oncogenic driver mutations.
- Patients with ALK-rearranged advanced NSCLC refractory to multiple ALK TKI generations typically receive chemotherapy, which has a poor prognosis.
